A modified fluctuation test applied to colorectal cancer cells shows that EGFR/BRAF inhibitor-induced persisters slowly proliferate and have an increased mutation rate. Error-prone DNA polymerases are identified as potential targets to avoid tumor recurrence following treatment with these drugs.Compelling evidence shows that cancer persister cells represent a major limit to the long-term efficacy of targeted therapies. However, the phenotype and population dynamics of cancer persister cells remain unclear. We developed a quantitative framework to study persisters by combining experimental characterization and mathematical modeling. We found that, in colorectal cancer, a fraction of persisters slowly replicates. Clinically approved targeted therapies induce a switch to drug-tolerant persisters and a temporary 7- to 50-fold increase of their mutation rate, thus increasing the number of persister-derived resistant cells. These findings reveal that treatment may influence persistence and mutability in cancer cells and pinpoint inhibition of error-prone DNA polymerases as a strategy to restrict tumor recurrence.
A modified fluctuation-test framework characterizes the population dynamics and mutation rate of colorectal cancer persister cells / M. Russo, S. Pompei, A. Sogari, M. Corigliano, G. Crisafulli, A. Puliafito, S. Lamba, J. Erriquez, A. Bertotti, M. Gherardi, F. Di Nicolantonio, A. Bardelli, M. Cosentino Lagomarsino. - In: NATURE GENETICS. - ISSN 1546-1718. - 54:7(2022), pp. 976-984. [10.1038/s41588-022-01105-z]
A modified fluctuation-test framework characterizes the population dynamics and mutation rate of colorectal cancer persister cells
M. Gherardi;M. Cosentino Lagomarsino
Ultimo
2022
Abstract
A modified fluctuation test applied to colorectal cancer cells shows that EGFR/BRAF inhibitor-induced persisters slowly proliferate and have an increased mutation rate. Error-prone DNA polymerases are identified as potential targets to avoid tumor recurrence following treatment with these drugs.Compelling evidence shows that cancer persister cells represent a major limit to the long-term efficacy of targeted therapies. However, the phenotype and population dynamics of cancer persister cells remain unclear. We developed a quantitative framework to study persisters by combining experimental characterization and mathematical modeling. We found that, in colorectal cancer, a fraction of persisters slowly replicates. Clinically approved targeted therapies induce a switch to drug-tolerant persisters and a temporary 7- to 50-fold increase of their mutation rate, thus increasing the number of persister-derived resistant cells. These findings reveal that treatment may influence persistence and mutability in cancer cells and pinpoint inhibition of error-prone DNA polymerases as a strategy to restrict tumor recurrence.File | Dimensione | Formato | |
---|---|---|---|
s41588-022-01105-z_compressed.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
2.97 MB
Formato
Adobe PDF
|
2.97 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.